Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report published on Monday morning.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Abeona Therapeutics Trading Down 0.6 %

NASDAQ ABEO opened at $5.12 on Monday. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $8.45. The company has a 50 day moving average price of $5.43 and a 200 day moving average price of $5.83. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $222.57 million, a PE ratio of -1.90 and a beta of 1.79.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. As a group, sell-side analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ABEO. Twinbeech Capital LP acquired a new position in Abeona Therapeutics in the 4th quarter worth approximately $58,000. Northern Trust Corp boosted its holdings in shares of Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 11,478 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Abeona Therapeutics during the fourth quarter worth $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the third quarter valued at $84,000. Finally, Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics in the fourth quarter valued at $118,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.